Form 4: Soleno Therapeutics Executive Meredith Manning Reports Acquisition of Shares and Stock Options
SEC Form 4 Filing
Meredith Manning, Chief Commercial Officer of Soleno Therapeutics, reports the acquisition of common stock and stock options.
Summary
- Meredith Manning, Chief Commercial Officer of Soleno Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On January 21, 2025, Manning acquired 13,600 shares of common stock in the form of restricted stock units (RSUs) at $0.
- Manning also acquired options to purchase 29,200 shares of common stock at an exercise price of $49.17, exercisable starting February 1, 2025, and expiring on January 21, 2035.
- Following these transactions, Manning beneficially owns 53,600 shares of common stock and options for 29,200 shares.
- The RSUs vest in quarterly installments, while the stock options vest monthly, contingent upon continued service with Soleno Therapeutics.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions. The acquisition of shares and options by an executive is generally viewed as a positive sign, but it's not a strong indicator of overall company performance.
Positives
- The acquisition of shares and stock options by a key executive demonstrates confidence in the company's future prospects.
- The vesting schedules for the RSUs and stock options incentivize continued service and commitment from the Chief Commercial Officer.
Future Outlook
The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules suggest a long-term commitment from the executive.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- The transactions reported in the Form 4 filing may have a minor positive impact on shareholder sentiment, as they indicate confidence from a key executive.
Key Dates
| Date | Description |
|---|---|
| December 15, 2024 | First annual vesting date for 1/4th of the RSUs. |
| January 21, 2025 | Date of transaction: acquisition of common stock (RSUs) and stock options. |
| February 1, 2025 | First monthly vesting date for 1/48th of the shares subject to the stock option. |
| January 21, 2035 | Expiration date of the employee stock options. |
Keywords
Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, SLNO, Soleno Therapeutics, Meredith Manning, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.